Benitec Biopharma (BNTC) EBT Margin (2019 - 2023)

Benitec Biopharma has reported EBT Margin for 5 years, with the latest figure at 234828.57% in Q2 2023.

• Quarterly EBT Margin changed N/A year-over-year to 234828.57% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 5689871.43% (down 565679349.0% YoY) and the FY2023 annual result came in at 41292.0%, up 777512.0% from the prior year.
• EBT Margin declined to 234828.57% in Q2 2023 per BNTC's latest filing, from 10818.52% in the prior quarter.
• Over five years, EBT Margin peaked at 46220.0% in Q2 2020 and troughed at 380100.0% in Q1 2021.
• A 5-year average of 94732.58% and a median of 10818.52% in 2023 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2021 and 2022: EBT Margin plunged 37256071 bps in 2021, then surged 37260000 bps in 2022.
• Over 5 years, EBT Margin stood at 2741.56% in 2019, then tumbled by 12966 bps to 358200.0% in 2020, then soared by 94 bps to 19948.0% in 2021, then tumbled by 127 bps to 45264.29% in 2022, then plunged by 419 bps to 234828.57% in 2023.
• According to Business Quant data, EBT Margin over the past three periods registered 234828.57%, 10818.52%, and 45264.29% for Q2 2023, Q1 2023, and Q4 2022 respectively.